Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines

Gastric Cancer

Volumn 6, Issue SUPPL. 1, 2003, Pages 66-70

  Usuki, Hisashi ^a   Ishimura, Ken ^a   Yachida, Shinichi ^a   Hagiike, Masanobu ^a   Okano, Keiichi ^a   Izuishi, Kunihiko ^a   Karasawa, Yukihiko ^a   Goda, Fuminori ^a   Maeta, Hajime ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Dehydrogenase; Dihydropyrimidine; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; UFT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CATABOLISM; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE PROGRESSION; DRUG COMBINATIONS; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; JAPAN; LEUCOVORIN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; OXIDOREDUCTASES; OXONIC ACID; PERITONEAL NEOPLASMS; PROGNOSIS; PYRIDINES; STATISTICS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0038584860     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0225-8     Document Type: Conference Paper

References (16)

1. Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt) 1999;13:17-21.
2. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980;71:112-23.
3. Ohwada S, Ogawa T, Izumi M, Inoue T, Teshigawara O, Ikeya T, et al. Effects of 5′-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients. Anticancer Res 1997;17:2313-8.
4. Bertino JR, Sawicki WL, Lindquist CA, Gupta VS. Scheduledependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977;37:327-8.
5. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981;41:3288-95.
6. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, et al. Treatment of advanced colorectal and gastricadenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-96.
7. Majima H. Phase I and preliminary phase II study of coadministration of uracil and FT-207 (UFT therapy). Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1980;7:1383-7.
8. Baccanari DP, Davis ST, Knick VC, Spector T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci U S A 1993;90:11064-8.
9. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
10. Shirasaka T, Fujita F, Fujita M, Fukushima M, Taguchi T, Fujii S. Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1990;17:1871-6.
11. Sasaki T. New anti-cancer drugs for gastrointestinal cancers. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1997;24:1925-31.
12. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-55.
13. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000;17:33-8.
14. Maruyama K, Sasako M, Sano T, Katai H, Kino I, Kato Y, et al. Operative procedures. In: Nishi M, Omori Y, Miwa K, editors. Japanese classification of gastric carcinoma. First English Ed. Tokyo: Kanehara: 1995. p 14-16.
15. Bateman JR, Pugh RP, Cassidy FR, Marshall GJ, Irwin LE. 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971;28:907-13.
16. Saji S, Aiba K, Araki H, Sasaki K, Shirasaka T, Sowa M, et al. Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors - nationwide questionnaire survey. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1997;24:1892-900.